Thrivent Financial For Lutherans Global Blood Therapeutics, Inc. Transaction History

Thrivent Financial For Lutherans

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	SELL	$22.3 - $37.39 $74,638 - $125,144	-3,347 Reduced 6.26%	50,137 $1.6 Million
Q1 2022 May 13, 2022	SELL	$25.68 - $35.59 $1,412 - $1,957	-55 Reduced 0.1%	53,484 $1.85 Million
Q4 2021 Feb 16, 2022	BUY	$24.9 - $40.26 $6,772 - $10,950	272 Added 0.51%	53,539 $1.57 Million
Q3 2021 Nov 15, 2021	BUY	$25.48 - $37.34 $8,382 - $12,284	329 Added 0.62%	53,267 $1.36 Million
Q2 2021 Aug 19, 2021	BUY	$32.46 - $43.42 $27,493 - $36,776	847 Added 1.63%	52,938 $1.85 Million
Q1 2021 May 17, 2021	SELL	$38.94 - $50.85 $3.33 Million - $4.34 Million	-85,437 Reduced 62.12%	52,091 $2.12 Million
Q4 2020 Feb 16, 2021	BUY	$37.65 - $63.77 $1.71 Million - $2.89 Million	45,380 Added 49.25%	137,528 $5.96 Million
Q3 2020 Nov 10, 2020	BUY	$52.76 - $74.49 $4.12 Million - $5.81 Million	78,037 Added 553.02%	92,148 $5.08 Million
Q1 2020 May 15, 2020	BUY	$41.72 - $87.2 $588,710 - $1.23 Million	14,111 New	14,111 $720,000

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.